儿童多发性硬化的疾病进展与复发活动
这项基于意大利多发性硬化登记的前瞻性队列研究纳入16130例多发性硬化患者,比较儿童起病、成人起病与晚发起病患者的进展独立于复发活动(PIRA)和复发相关恶化(RAW)。儿童起病患者较成人起病和晚发起病患者残疾更轻、疾病活动更明显、接受疾病修饰治疗(DMT)时间更长,PIRA发生率更低。延迟启动DMT与PIRA和RAW风险升高相关。
要点
- 儿童起病多发性硬化患者PIRA发生率为40.4%,低于成人起病的44.3%和晚发起病的56.8%(P < .001)。
- 起病年龄越大PIRA风险越高:成人起病 vs 儿童起病HR 1.42(95% CI 1.30-1.55),晚发起病 vs 儿童起病HR 2.98(95% CI 2.60-3.41)。
- 延迟启动DMT与PIRA风险升高相关(HR 1.16;95% CI 1.00-1.34;P = .04)及RAW风险升高相关(HR 1.75;95% CI 1.28-2.39;P = .001)。
核心结论
- PIRA可发生于任何年龄,儿童起病虽不能完全防止疾病进展,但研究提示儿童起病患者在约十年随访中较少出现PIRA。
- 这些数据也支持在儿童起病多发性硬化患者中启动DMT的获益,因治疗与PIRA和RAW发生减少相关,且与起病年龄无关。
研究设计与样本
- 本研究为基于意大利多发性硬化登记前瞻性获取数据的队列研究,执行时间为2000年6月1日至2021年9月30日。
- 数据提取时登记库中有来自120个多发性硬化中心的73564例患者的纵向数据。
- 应用纳入和排除标准后,研究评估了16130例多发性硬化患者,起病年龄中位数(IQR)为28.7(22.8-36.2)岁,女性占68.3%。
主要发现
- 首次48周确认的PIRA发生于7176例患者(44.5%):儿童起病558例(40.4%)、成人起病6258例(44.3%)、晚发起病360例(56.8%)(P < .001)。
- 与PIRA相关的因素包括起病年龄较大(成人起病 vs 儿童起病HR 1.42;95% CI 1.30-1.55;晚发起病 vs 儿童起病HR 2.98;95% CI 2.60-3.41;P < .001)、病程较长(HR 1.04;95% CI 1.04-1.05;P < .001)和DMT暴露时间较短(HR 0.69;95% CI 0.64-0.74;P < .001)。
- PIRA的累积发生率在20岁时为1.3%,21至30岁之间约增加7倍至9.0%,40至70岁每增加一个年龄十年几乎翻倍(40岁21.6%、50岁39.0%、60岁61.0%、70岁78.7%)。
- RAW事件的累积发生率从20岁至60岁呈相似趋势(20岁0.5%、30岁3.5%、40岁7.8%、50岁14.4%、60岁24.1%),70岁时未进一步增加(27.7%)。
- 延迟启动DMT与PIRA风险升高相关(HR 1.16;95% CI 1.00-1.34;P = .04)及RAW风险升高相关(HR 1.75;95% CI 1.28-2.39;P = .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) are protected against disability because of greater capacity for repair. OBJECTIVE: To assess the incidence of and factors associated with progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in POMS compared with typical adult-onset MS (AOMS) and late-onset MS (LOMS). DESIGN, SETTING, AND PARTICIPANTS: This cohort study on prospectively acquired data from the Italian MS Register was performed from June 1, 2000, to September 30, 2021. At the time of data extraction, longitudinal data from 73 564 patients from 120 MS centers were available in the register. MAIN OUTCOMES AND MEASURES: The main outcomes included age-related cumulative incidence and adjusted hazard ratios (HRs) for PIRA and RAW and associated factors. EXPOSURES: Clinical and magnetic resonance imaging features, time receiving disease-modifying therapy (DMT), and time to first DMT. RESULTS: After applying the inclusion and exclusion criteria, the study assessed 16 130 patients with MS (median [IQR] age at onset, 28.7 [22.8-36.2 years]; 68.3% female). Compared with AOMS and LOMS, patients with POMS had less disability, exhibited more active disease, and were exposed to DMT for a longer period. A first 48-week-confirmed PIRA occurred in 7176 patients (44.5%): 558 patients with POMS (40.4%), 6258 patients with AOMS (44.3%), and 360 patients with LOMS (56.8%) (P < .001). Factors associated with PIRA were older age at onset (AOMS vs POMS HR, 1.42; 95% CI, 1.30-1.55; LOMS vs POMS HR, 2.98; 95% CI, 2.60-3.41; P < .001), longer disease duration (HR, 1.04; 95% CI, 1.04-1.05; P < .001), and shorter DMT exposure (HR, 0.69; 95% CI, 0.64-0.74; P < .001). The incidence of PIRA was 1.3% at 20 years of age, but it rapidly increased approximately 7 times between 21 and 30 years of age (9.0%) and nearly doubled for each age decade from 40 to 70 years (21.6% at 40 years, 39.0% at 50 years, 61.0% at 60 years, and 78.7% at 70 years). The cumulative incidence of RAW events followed a similar trend from 20 to 60 years (0.5% at 20 years, 3.5% at 30 years, 7.8% at 40 years, 14.4% at 50 years, and 24.1% at 60 years); no further increase was found at 70 years (27.7%). Delayed DMT initiation was associated with higher risk of PIRA (HR, 1.16; 95% CI, 1.00-1.34; P = .04) and RAW (HR, 1.75; 95% CI, 1.28-2.39; P = .001). CONCLUSIONS AND RELEVANCE: PIRA can occur at any age, and although pediatric onset is not fully protective against progression, this study's findings suggest that patients with pediatric onset are less likely to exhibit PIRA over a decade of follow-up. However, these data also reinforce the benefit for DMT initiation in patients with POMS, as treatment was associated with reduced occurrence of both PIRA and RAW regardless of age at onset.
引用
- Iaffaldano P, Portaccio E, Lucisano G, et al. Multiple Sclerosis Progression and Relapse Activity in Children. JAMA Neurol. 2024. PMID: 38010712. doi:10.1001/jamaneurol.2023.4455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。